Akcea Therapeutics, Inc.
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From Akcea Therapeutics, Inc.
The US firm has sold some of its royalty stream for the gene therapy Spinraza and cardiovascular drug candidate, pelacarsen, to Royalty Pharma for $500m upfront, which should help fund upcoming milestones for Ionis’ late-stage pipeline.
Private Company Edition: 5AM revealed two funds totaling $450m and $300m, V-Bio raised a €110m venture capital fund and AXA IM Alts committed $500m for health care private equity deals. Also, TRIANA launched with $110m and the AMR Action Fund backs Adaptive Phage Therapeutics.
Private Company Edition: In addition to Adiso, Creyon recently launched with $40m and TRexBio extended its series A by $26m to $85m total. Also, Kurma Partners raised the first €160m of a planned €250m fund to back companies transitioning from R&D to commercial operations.
The decision followed the November 2021 announcement that while a Phase IIb study hit its primary endpoint, the magnitude of benefit was too small and adverse event rate too high.
- Antisense, Oligonucleotides
All set! This article has been sent to email@example.com.
All fields are required. For multiple recipients, separate email addresses with a semicolon.